GENinCode

Executive Summary

GENinCode is a UK-based biotechnology company developing genetic testing and risk assessment tools for cardiovascular and metabolic diseases. By integrating monogenic, polygenic, and clinical data with artificial intelligence, the company offers advanced predictive risk scores designed to enable preventive care. Its flagship product, CARDIO inCode-Score®, aims to improve the prediction and prevention of cardiovascular disease, a leading global cause of mortality. The company leverages a proprietary algorithm to provide personalized risk assessments, which could significantly enhance early intervention strategies and reduce healthcare costs. While GENinCode operates in a competitive landscape, its focus on combining multiple data types and AI-driven analysis differentiates its platform. As a private company, it has not disclosed funding or valuation, but its technology holds potential for broad clinical adoption.

Upcoming Catalysts (preview)

• Q3 2026FDA or CE Mark clearance for CARDIO inCode-Score®40% success
• 2026Strategic partnership with a major healthcare provider or insurer50% success
• H2 2026Publication of clinical validation data in peer-reviewed journal60% success